• Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Compositions of Matter and Methods of Use for MANF

• Patent Issuance Will Provide Additional IP Protection for MANF Protein Therapy and Cell Therapy

SAN FRANCISCO and GENEVA, May 5, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application Serial No. 13/305,025 entitled, "Dopaminergic Neuronal Survival Promoting Factors and Uses Thereof." Upon issuance, the patent will provide additional intellectual property protection for MANF (mesencephalic-astrocyte-derived neurotrophic factor) protein therapy and cell therapy. The allowed patent claims cover compositions of matter and methods of use related to the Company's proprietary manufacturing process for synthetic MANF and its administration.

• Lead Product MSPrecise(R): Clinically Validated, First-In-Class Next-Generation Sequencing (NGS) Assay that Identifies Multiple Sclerosis (MS) at First Clinical Presentation
• Recent Prospective Study at 13 U.S. Centers of MS Excellence Demonstrated the Significant Diagnostic Accuracy of MSPrecise
• Platform for Comprehensive Molecular Profiling of Immune-mediated Neurodegenerative Diseases

Since the publication of our Executive Informational Overview® (EIO) on Amarantus BioScience Holdings, Inc. (AMBS-OTC) in early September 2014, the company has advanced development of each of its three lead programs. Amarantus published data from a 72-patient study of the LymPro Test® demonstrating the test’s accuracy at identifying patients with moderate-to-severe Alzheimer's Disease versus healthy controls, completed enrollment of an expanded 140-patient study of LymPro for which results are expected by mid-December 2014, submitted its Phase 2b trial design for Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia to the FDA for review and written feedback, and submitted an Orphan Drug application to the FDA for MANF in retinitis pigmentosa, a degenerative eye disease. By the end of 2014, Amarantus expects to be able to launch the LymPro Test® for research markets (Investigational Use Only), and believes it can use the data from the expanded 140-patient LymPro study in support of a broader product launch in 2015.

On Monday, November 10, Amarantus Bioscience Holdings, Inc. started off the earnings week by reporting its third quarter 2014 (ended September 30) financial results. The company also recapped its milestones, updated investors on its product development status, and teased a potential new acquisition for the coming weeks. Lastly, the company also announced a strategic financing agreement with Dominion Capital that raises $3 million for Amarantus and extinguishes a prior promissory note held by Dominion. 

Biotechnology company Amarantus Bioscience Holdings, Inc. (AMBS-OTC) reported this morning that it had applied to the U.S. Food & Drug Administration (FDA) for Orphan Drug Designation for MANF (mesencephalic-astrocyte-derived neurotrophic factor) in retinitis pigmentosa. The company's stock appeared to be responding well to the news, and was up over 9% as of 11 am (ET).

Biotech company Amarantus Bioscience Holdings, Inc. (AMBS-OTC) has reported positive data from its LP-002 study of the Lymphocyte Proliferation Test (LymPro Test) blood diagnostic for Alzheimer's disease (AD). LymPro achieved highly statistically significant results in correctly distinguishing patients with moderate-to-severe AD from healthy controls. As a result of these positive findings, Amarantus is expanding the study to assess LymPro's predictive value in diagnosing early-stage AD patients. Amarantus anticipates launching LymPro in the fourth quarter of 2014.

Amarantus BioScience Holdings, Inc. (AMBS-OTC) provided investors with an important update today regarding the company's plans to initiate a Phase 2b clinical study of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia, or PD-LID.

A new clinical study published Tuesday in the British Medical Journal, identified a possible link between long-term use of benzodiazepines and Alzheimer's disease. Researchers examined close to 1,800 Alzheimer's patients who had at least six years of medical data and who had used benzodiazepines at least five years before their Alzheimer's diagnosis, and compared these cases to over 7,100 control patients. All medical records used in the study were from patients over 66 years of age.

Today, Crystal Research Associates has issued a 76-page Executive Informational Overview® (EIO) on California biopharmaceutical company Amarantus BioScience Holdings, Inc. (AMBS-OTC). The EIO details the Company's pipeline development, business model, growth strategies, market opportunities, potential milestones, competitive landscape, financial position, business risks, and more. It is available for download on our website here. A summary of Amarantus' 12 competitive advantages in its target diagnostics and therapeutics fields is available here: Amarantus' Key Points.